Definium Therapeutics, Inc. 8-K

What Happened

• On June 22, 2026, Definium Therapeutics, Inc. announced positive topline data from its Phase 3 Emerge study of DT120 ODT for the treatment of major depressive disorder. The company furnished a press release (Exhibit 99.1) and posted a presentation discussing the topline data on its website (Exhibit 99.2), both of which were included with the Form 8-K filing.

Key Details

• Date of disclosure: June 22, 2026.
• Study: Phase 3 Emerge study of DT120 ODT for major depressive disorder.
• Company materials: Press release (Exhibit 99.1) and topline data presentation (Exhibit 99.2) were furnished/posted and incorporated by reference in the 8-K.

Why It Matters

• A positive Phase 3 topline announcement is a material clinical milestone for a development-stage biopharma company; it can affect the company’s regulatory path, development timing and investor expectations.
• Investors should review the press release and presentation for detailed efficacy and safety results, and monitor upcoming regulatory updates, detailed study data, and any management commentary or next-step plans that Definium files or announces.